Aerobic Exercise-induced Effect on Cardiorespiratory Fitness, Endothelial Function, and Brain-derived Neurotrophic Factor in Patients With Ischaemic Heart Disease (ENDO-R)
Ffect of Different Aerobic Exercise Protocols in Cardiac Rehabilitation on Cardiorespiratory Fitness, Endothelial Function, and Brain-derived Neurotrophic Factor in Patients With Ischaemic Heart Disease (ENDO-R)
Ischaemic heart disease (IHD) remains the leading cause of cardiovascular mortality worldwide. Low peak oxygen uptake (VO2 peak), endothelial dysfunction, and reduced levels of brain-derived neurotrophic factor (BDNF) are well-established independent prognostic markers in IHD. Cumulative evidence indicates that aerobic exercise-based cardiac rehabilitation (CR) is an effective non-pharmacological therapy to improve these markers.
Although high-intensity interval training (HIIT) has been shown to enhance VO2 peak and endothelial function to a greater extent than moderate-intensity continuous training (MICT), the influence of high-intensity bout duration on these exercise-induced adaptations remains unclear. Notably, a previous meta-analysis by our group demonstrated that only long-interval HIIT (L-HIIT; > 1 min) yielded superior improvements in endothelial function, whereas short-interval HIIT (S-HIIT; ≤ 1 min) showed no significant differences compared to MICT. To date, no clinical trial has directly compared L-HIIT, S-HIIT, and MICT. Furthermore, to the best of our knowledge, there is no evidence regarding the effect of high-intensity bout duration on VO2 peak and BDNF adaptations in patients with IHD. Therefore, the main objective of this project will be to compare the effect of the three aerobic exercise methods on CRF, endothelial function, and BDNF concentration in patients with IHD. Complementarily, the effect of aerobic exercise, depending on the exercise method, on different mortality predictors will be compared. For this purpose, a multicentre randomised study will be carried out (2 hospitals in Elche and one in Alicante). Assessors will be blinded to the patients allocation. Participants will be aware about their allocation in the experimental groups due to the nature of the study. A total of 111 men and women with IHD, diagnosed between three and 12 months before the start of the intervention, aged between 45 and 75 years, and without limitations for the practice of exercise training, will be recruited. All patients will train 3 days a week for 12 weeks. Participants will be assessed before the intervention (i.e., pre), at 6 weeks of training (i.e., mid) ,and after the intervention (i.e., post). Physiological and psychological variables will be registered in the assessment periods. Training intensity will be individually prescribed based on the cardiopulmonary exercise test (CPET). Intensity exercise will be adapted after the first part of the intervention. Analysis of covariance will be used to compare the values of the three groups after the intervention for the continuous variables, including the pre-intervention value as a covariate, while a logistic regression model will be used for the categorical variables.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jose Manuel Sarabia, PhD
- Phone Number: 965222568
- Email: jsarabia@umh.es
Study Contact Backup
- Name: Agustin Manresa Rocamora, PhD
- Phone Number: 626542131
- Email: amanresa@umh.es
Study Locations
-
-
-
Alicante, Spain, 03010
- Recruiting
- Instituto de Investigación Sanitaria y Biomédica de Alicante
-
Contact:
- Carles Blasco, Master
- Phone Number: 965 913 941
- Email: blasco_car@isabial.es
-
-
Alicante
-
Elche, Alicante, Spain, 03202
- Recruiting
- Centro de Investigación del deporte
-
Contact:
- José M Sarabia Marín, PhD
- Phone Number: +34965222568
- Email: jsarabia@umh.es
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged between 45 and 75 years.
- Diagnosed with acute myocardial infarction, unstable or stable angina.
- Treated with percutaneous coronary intervention, coronary artery bypass grafting, or conservative treatment.
- Event or intervention within 3 to 12 months prior to participation in the study.
- Fluency in speaking and reading Spanish.
- Residing in Elche or surrounding areas and able to attend evaluations and the exercise programme (not planning to be absent for more than one week during the programme).
- Functional Class I-II according to the New York Heart Association (NYHA) classification.
- No physical limitations for exercise.
- Stable optimal medical treatment.
- Physically inactive, defined as 1) not meeting the World Health Organization recommendations for both aerobic and strength exercise, and 2) not participating in a structured exercise programme at least 3 days per week for more than 3 months. Both conditions must be met for inclusion. Note: Casual walking is not considered grounds for exclusion.
Exclusion Criteria:
- Use of walking assistive devices.
- Treatment with chemotherapy for any type of cancer in the past 2 years.
- Hospitalisation in an intensive care unit in the past 6 months for reasons other than the ischaemic event.
- Acute myocardial infarction group IV Killip-Kimball.
- Obesity grade III (≥40.0 kg/m²).
- Medical contraindication for inclusion in an exercise programme.
- Diabetes with uncontrolled blood glucose levels.
- Poorly controlled hypertension: resting blood pressure > 180/110 mmHg.
- Chest pain with exertion or ST-segment changes suggestive of residual ischemia during ergometry. Residual ischemia.
- Severely reduced functional capacity on initial ergometry (<5 metabolic equivalent of task).
- Left ventricular ejection fraction less than 50%.
- Severe stenosis of the left main coronary artery (>50% significant disease).
- Severe aortic stenosis, left ventricular outflow tract obstruction (e.g., obstructive hypertrophic cardiomyopathy) or aortic dissection.
- Severe valvulopathy.
- Acute pulmonary embolism or deep vein thrombosis.
- Severe pulmonary hypertension.
- Acute heart failure.
- Acute endocarditis, myocarditis, or pericarditis.
- Acute or chronic renal insufficiency (estimated glomerular filtration rate <30 ml/min).
- Pulmonary fibrosis or interstitial disease (severe respiratory insufficiency or confirmed chronic obstructive pulmonary disease).
- Uncontrolled cardiac arrhythmias/hemodynamically unstable.
- Permanent or persistent/paroxysmal atrial fibrillation with episodes in the past 6 months.
- High-grade cardiac block.
- Presence of implantable devices: cardiac resynchronization therapy pacemaker, implantable cardioverter defibrillators, or pacemaker.
- Presence of ischaemic symptoms during the incremental exercise test performed before the intervention.
- Severe autonomic or peripheral neuropathy.
- Use of nitrates in pharmacological treatment.
- Any planned surgical or medical intervention during the study period.
- Plans to participate in or current participation in other studies that may interfere with this study.
- Current pregnancy or intention to become pregnant during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Moderate-intensity continuous training (MICT) group
Continuous exercise training on a cycle ergometer |
Patients allocated to the MICT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will cycle continuously between the first and second ventilatory thresholds. The duration of each exercise session will be set according to the estimated energy expenditure of the long HIIT and short HIIT groups for each training block (energy expenditure-adjusted exercise sessions). All sessions will be supervised, and patients will be asked to avoid additional exercise. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations. |
|
Experimental: Short high-intensity interval training (HIIT) group
High-intensity interval exercise performed on a cycle ergometer |
Patients allocated to the Short HIIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-repetition sets of 1-min above the second ventilatory threshold. Patients will perform 1- and 3-min active recovery periods below the first ventilatory threshold between repetitions and sets, respectively. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations. |
|
Experimental: Long high-intensity interval training (HIIT) group
High-intensity interval exercise performed on a cycle ergometer |
Patients allocated to the Long HIIT will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-min high-intensity exercise bouts above the second ventilatory threshold separated by 4-min active recovery periods below the first ventilatory threshold. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in endothelial function at 8 weeks
Time Frame: 8 weeks
|
Endothelial function (i.e., endothelial-dependent dilation) will be assessed by brachial FMD. |
8 weeks
|
|
Change from baseline in endothelial function at 15 weeks
Time Frame: 15 weeks
|
Endothelial function (i.e., endothelial-dependent dilation) will be assessed by brachial FMD. |
15 weeks
|
|
Change from baseline in VO2 peak at 8 weeks
Time Frame: 8 weeks
|
Participants will perform a symptom-limited CPET on a cycle ergometer. |
8 weeks
|
|
Change from baseline in VO2 peak at 15 weeks
Time Frame: 15 weeks
|
Participants will perform a symptom-limited CPET on a cycle ergometer. |
15 weeks
|
|
Change from baseline in resting serum BDNF concentration at 8 weeks
Time Frame: 8 weeks
|
Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before the CPET. |
8 weeks
|
|
Change from baseline in resting serum BDNF concentration at 15 weeks
Time Frame: 15 weeks
|
Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before the CPET. |
15 weeks
|
|
Change from baseline in exercise-induced effect on serum BDNF at 8 weeks
Time Frame: 8 weeks
|
Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before and after the CPET. |
8 weeks
|
|
Change from baseline in exercise-induced effect on serum BDNF at 15 weeks
Time Frame: 15 weeks
|
Blood samples will be obtained through an indwelling catheter placed in the antecubital vein before and after the CPET. |
15 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in endothelial-independent dilation at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
Brachial NMD will be used to measure endothelial-independent dilation. |
8 and 15 weeks
|
|
Change from baseline in pulmonary function at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
Pulmonary function will be measured by spirometry |
8 and 15 weeks
|
|
Change from baseline in resting cardiopulmonary parameters at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
Patients will be asked to rest for 5 min before stating the CPET. |
8 and 15 weeks
|
|
Change from baseline in cardiopulmonary parameters at first and second ventilatory thresholds at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
First and second ventilatory threshold during the CPET will be analysed blindly using the ventilatory equivalents method. |
8 and 15 weeks
|
|
Change from baseline in peak cardiopulmonary parameters at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
8 and 15 weeks
|
|
|
Change from baseline in cardiopulmonary variables measured during the recovery at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
Cardiopulmonary variables will be measured during the 3-min recovery period of the CPET. |
8 and 15 weeks
|
|
Change from baseline in ventilatory efficiency at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
Ventilatory-related variables will be measured during the CPET. |
8 and 15 weeks
|
|
Change from baseline in MacNew domains at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
The MacNew heart disease health-related quality of life instrument will be used as a disease-specific quality of life questionnaire. The MacNew consists of 27 items that fall into three domains (a 13-item physical limitations domain scale, a 14-item emotional function domain scale, and a 13-item social function domain scale). Scoring of the MacNew is straightforward. The maximum possible score in any domain is 7 (high quality of life) and the minimum is 1 (poor quality of life). |
8 and 15 weeks
|
|
Change from baseline in body composition at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
Bioimpedance assessment will be conducted in fasting state. |
8 and 15 weeks
|
|
Change from baseline in resting heart rate variability (HRV) at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
HRV will be measured after an overnight fasting period at the same time of day |
8 and 15 weeks
|
|
Change from baseline in echocardiographic variables at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
A resting echocardiographic assessment will be performed before starting the CPET. The echocardiographic variables measured will be left ventricular end-diastolic diameter, septal and posterior wall thickness, left atrium dimension and volume, left ventricular ejection fraction (four-chamber and biplane Simpson's method, tricuspid annular plane systolic excursion, S' wave velocity, peak E and A wave velocities (in sinus rhythm), lateral and medial e' velocities, peak tricuspid regurgitation gradient, and velocity and gradient across the aortic valve. |
8 and 15 weeks
|
|
Change from baseline in blood analysis variables at 15 weeks.
Time Frame: 15 weeks
|
Blood samples will be obtained after at least a 10-hours period of fasting. |
15 weeks
|
|
Change from baseline in ability to inhibit cognitive interference at 8 and 15 weeks
Time Frame: 8 and 15 weeks
|
The Stroop test will be used to assess the ability to inhibit cognitive interference. |
8 and 15 weeks
|
|
Change from baseline in verbal memory performance at 15 weeks
Time Frame: 15 weeks
|
Verbal learning and memory are assessed using the Rey Auditory Verbal Learning Test (RAVLT) under standardized environmental conditions. The procedure begins with five consecutive learning trials of a 15-word list (List A). The primary measures focus on the recall performance of this list at three key points during the test: Immediate post-interference recall (A6): After presenting a new distractor list (List B), participants are asked to recall the original List A to assess resistance to interference. 20-minute delayed recall (A7): Assesses short-term retention. During this interval, participants complete the Corsi Block-Tapping Test (a visuospatial task) to prevent mental rehearsal of the words. 24-hour delayed recall (A8): Measures long-term memory consolidation via an unexpected telephone call where participants are asked to recall List A once again. |
15 weeks
|
|
Change from baseline in visuospatial working memory performance at 15 weeks
Time Frame: 15 weeks
|
Visuospatial working memory is assessed using the Corsi Block-Tapping Test. Participants reproduce sequences of tapped blocks in both forward (same order) and backward (reverse order) conditions. Sequence lengths increase progressively until the participant fails two sequences of the same length. The reported outcome includes the Corsi span (defined as the maximum sequence length correctly reproduced) and the total number of correctly reproduced sequences. For both metrics, higher scores indicate better visuospatial working memory performance. This task is administered during the 20-minute interval of the RAVLT to prevent mental rehearsal of verbal material. |
15 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Vascular Diseases
- Cardiovascular Diseases
- Heart Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Myocardial Ischemia
- Chest Pain
- Angina Pectoris
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Coronary Artery Disease
- Angina, Stable
- Angina, Unstable
- Motor Activity
- Movement
- Musculoskeletal Physiological Phenomena
- Musculoskeletal and Neural Physiological Phenomena
- Exercise
Other Study ID Numbers
Other Study ID Numbers
- PI2023/154
- ISABIAL (Registry Identifier: ISABIAL: 2023-0447 / CEIm: PI2023/154)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL) Community in ZENODO. Depositing in ZENODO allows selecting the type of access for each file (open, embargoed; restricted; closed) and the license for use (Creative Commons Attribution 4.0 International, which requires citing the database and the original study, as well as mentioning any changes made; this is suggested at the institutional level for files identified with open access). It is important to note that the use of ZENODO is temporary, until it is viable to use the REPISALUD repository, from the Carlos III Health Institute, by the ISABIAL research community. At least two different files will be included: i) The one corresponding to the data set; ii) One or more files with complementary information about the characteristics of the variables and/or study metadata (project, authors, related publication, keywords, etc.).
IPD Sharing Time Frame
From November 2027 to November 2030
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.